Stock Tips: CSL battered and bloody, but for these experts it’s no time to sell

It’s no easy gig analysing share prices and company performance but somebody’s got to do it. Every week two experts from our Share Tips columnist pool give us their recommendations. 

Sean Conlan – Leyland Private Asset Management

BUY 

CSL (ASX:CSL)
We view the post result selloff as an overreaction. Incorporating more conservative FY26 forecasts compared to guidance, we see the current valuation as undemanding.

Bluescope Steel (ASX:BSL)
Improving Australian demand conditions and support for US price outcomes remain key to the thesis. Management continues to execute well, and the business looks well positioned, even as it drives further cost out.

HOLD 

Cochlear (ASX:COH)
We see COH’s current share price as fair, with near-term downside risk from services revenue and negative geographic mix.

Origin Energy (ASX:ORG)
ORG looks to be pricing much of the Kraken IPO into the share price already. Core assets like Energy Markets and APLNG valuation outlook appears flat.

SELL

Audinate (ASX:AD8)
After two downgrades and with investor expectations still rebasing, there is limited evidence of a near-term recovery.

The Lottery Corporation (ASX:TLC)
We believe the deterioration in Powerball’s like for like turnover in 2H25 will continue into at least 1H26.

Chris Watt – Bell Potter Group

BUY

Amcor (ASX:AMC)
Positioned for steady earnings from resilient packaging demand, disciplined cost control and strengthening free cash flow. Recent pullback and dependable dividends present an attractive entry point.

WiseTech Global (ASX:WTC)
Continues to scale CargoWise globally, driving high recurring revenue and margins. With a strong rollout pipeline and structural logistics digitisation tailwinds, we believe current momentum can continue.

HOLD

James Hardie (ASX:JHX)
Shows solid operational execution and share gains, but US housing cyclicality tempers near-term demand. Valuation fairly reflects medium term growth; therefore we rate it a Hold.

CSL (ASX:CSL)
Retains a compelling pipeline across plasma and vaccines. Near term margin pressure and uncertainty around restructuring costs and the Seqirus demerger create uncertainty in the near term.

 SELL

Wesfarmers (ASX:WES)
Faces soft discretionary demand and mixed retail margins across Bunnings and Kmart. The stock has had a stellar run however the earnings outlook doesn’t justify the current valuation.

ASX (ASX:ASX)
Carries rising regulatory and technology costs while delivering low single digit earnings growth. With limited catalysts and an expensive valuation, we struggle to see any upside from here.

The views, information, or opinions expressed in the interviews in this article are solely those of the interviewees and do not represent the views of Stockhead.

Stockhead does not provide, endorse or otherwise assume responsibility for any financial advice contained in this article.